cagrisema novo nordisk news

Novo Nordisk's next-gen obesity drug Cagrisema

Novo Nordisk defends next-gen obesity drug CagriSema, gives details of new trial

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed investors and wiped $125 billion from its market value.

devdiscourse · 41m

Novo Nordisk's Bold Bet: CagriSema's Next Chapter in Obesity Treatment

Novo Nordisk defends its obesity drug CagriSema despite disappointing late-stage trial data that significantly affected its market value. The company plans a new trial in 2025 due to positive weight-loss indicators,

Benzinga.com · 1d

Novo Nordisk Faces Investor Concerns Over Hybrid CagriSema Trial Results For Weight Loss

Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors question trial protocols and transparency as Novo plans a new study.

Wegovy sales double to boost Novo Nordisk's 4th quarter

Benzinga.com · 3h

Novo Nordisk Q4 Earnings: Wegovy Sales More Than Double, Seeks Regulatory Approval For Hybrid Weight Loss Drug In 2026

Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in 2025, with results expected in Q1.

Reuters · 7h

Wegovy sales double to boost Novo Nordisk's fourth quarter but slower growth predicted

Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the final quarter of 2024, with analysts and investors describing the results as "good enough" to ease nerves about stiff competition from rival Eli Lilly.

CNBC on MSN · 8h

Novo Nordisk posts net profit beat as Wegovy sales jump 107% in fourth quarter

Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring demand for its Wegovy obesity drugs.

Investors are growing anxious about Novo Nordisk’s silence since disappointing CagriSema weight loss drug results

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

NVO CLASS ACTION: BFA Law Alerts Novo Nordisk Investors of the Imminent March 25 Class Action Deadline

New York, New York-- (Newsfile Corp. - February 5, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Novo Nordisk (NYSE: NVO) and certain ...

Novo Nordisk's sales increased by 25% in Danish kroner and by 26% at constant exchange rates to DKK 290.4 billion in 2024

Financial report for the period 1 January 2024 to 31 December 2024 Operating profit increased by 25% in Danish kroner and by ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Novo Nordisk's next-gen obesity drug Cagrisema

Wegovy sales double to boost Novo Nordisk's 4th quarter

Trending now